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Summary
The development of diagnostic methods and screening leads to early detection of breast cancer, which is why aspira-
tions are moving towards more conservative local treatment methods. New, non invasive and minimally invasive methods, 
should att ain same local control, with less cosmetic defects, side eff ects and complications compared to standard surgery. 
Five methods are being researched in clinical trials: cryoablation, radiofrequency ablation, laser ablation, microwave abla-
tion and ablation by focused high intensity ultrasound waves. Although some results are promising, these methods need 
further technical development and prospective comparison with today’s golden standard - oncoplastic breast surgery.
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MINIMALNO INVAZIVNO LIJEČENJE RAKA DOJKE
Sažetak
Razvojem dijagnostičkih mogućnosti, i probira karcinom dojke se otkriva u sve ranijem stadiju, zbog čega se teži sve 
poštednijim metodama lokalnog liječenja tumora. Nove, neinvazivne i minimalno invazivne metode trebale bi pružiti jedna-
ku lokalnu kontrolu, ali uz manje kozmetske defekte, nuspojave i komplikacije u odnosu na kirurške zahvate. Trenutno je u 
istraživanju pet metoda: krioablacija, radiofrekvencijska ablacija, laserska ablacija, mikrovalna ablacija i ablacija fokusira-
nim ultrazvučnim valovima. Neke od navedenih metoda pokazuju ohrabrujuće rezultate, ali zahtijevajudodatno tehničko 
usavršavanje i prospektivnu usporedbu s današnjim zlatnim standardom - onkoplastičnim kirurškim zahvatima.
KLJUČNE RIJEČI: krioablacija, radiofrekventna ablacija, laser, microvalna ablacija, fokusirani ultrazvuk
INTRODUCTION
With development of diagnostic methods and 
screening, breast cancer is detected at an earlier 
stage, which is why aspirations in breast cancer 
treatment are moving towards more conserva-
tive methods. New, minimally invasive methods, 
which would att ainlocal control of breast conserv-
ing surgery, while reducing the frequency and se-
verity of complications, are being researched. The 
goal of these methods is to create less cosmetic de-
fects, less pain, and deliver faster patient recovery 
and lower treatment costs. In minimally invasive 
procedures, tumor tissue is destroyed by heating 
or freezing. Five methods are currently being re-
searched in clinical trials: cryoablation, radiofre-
quency ablation, laser ablation, microwave abla-
tion and ablation by focused high intensity ultra-
sound waves. The fi rst four methods are invasive 
and the ultrasound method is noninvasive. Abla-
tion techniques vary in their technical characteris-
tics, as well as applicability in clinical practice, 
and are thus considered methods which are still in 
research.
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EXAMINATION
Before choosing a noninvasive treatment of 
breast cancer, a detailed imagingestimating the 
extentof the tumor needs to be provided, as well 
as the position of the tumor in relation to the skin, 
pectoral muscle and heart. Extensive intraductal 
component and lobular invasive carcinoma need 
to be ruled out fi rst. Also, core needle biopsy 
should be done to obtain the necessary histology 
and immunohistochemistry data.
Since the ablation procedure can disrupt the 
lymphatic drainage of the breast, the sentinel 
lymph node (SLN) status needs to be determined 
prior to ablation. After ablation, it is necessary to 
perform a magnetic resonance imaging (MRI) to 
assess tumor destruction. Ablations which require 
MRI or ultrasound guidance need to be done by a 
physician with extensive experience in stereotac-
tic needle biopsy.
CRYOABLATION
Cryoablation effi  ciency in complete tumor 
ablation is between 36 and 93% (1-4). The best re-
sults are achieved in treatment of tumors smaller 
than 1.5 cm (3,4). Patients with tumors larger than 
2 cm are considered bad candidates for this type 
of treatment due to the presence of tumor exten-
sion which is not visible by ultrasound. Cryoabla-
tion can be used as a defi nitive form of treatment 
of large tumors and higher grade tumor in elderly 
patients with unresectable breast cancer and in 
patients who refuse surgery, without recurrence 
within 18 months (5,6). The procedure is usually 
performed by placing a 3-millimeter probe in the 
geometrical center of the tumor under ultrasound 
contro (7). The necrosis is achieved by freezing the 
tumor tissue and anoxia-induced damage to the 
tumor blood vessels. The procedure lasts for about 
30 – 40 minutes in total. Freezing (<40 to -160oC) is 
achieved by rapid expansion of argon gas or liq-
uid nitrogen, which creates a 4-7 cm large ice ball. 
A discrete hyperechoic ring visible by ultrasound 
marks the boundary of frozen and non-frozen tis-
sue. Margin of 1 cm around the tumor is necessary 
in order to achieve complete cell death. To prevent 
damage to the skin, saline should be injected be-
tween the skin and the ice ball during the proce-
dure, especialy if a distance between the ice ball 
and the skin is less than 5 mm. This kind of protec-
tion enables ablation of tumors close to the skin, 
which is not possible with ablation methods based 
on high temperature (8,9), The ice ball is melted 
passively or actively using helium, after which the 
probe is removed from the ball. Due to analgesic 
eff ect of ice, it is possible to perform the procedure 
under local anesthesia, which is a signifi cant ad-
vantage compared to high temperature based ab-
lationswhich usually require general anesthesia or 
intravenous sedation.
The only reported complication with cryoab-
lation is skin necrosis, which is a result of insuffi  -
cient distance between the ice ball and the skin. 
There have been no reported complications of 
damage to the pectoral muscle or chest wall. The 
histologic image of surgically removed tissue after 
2-4 weeks shows absence of tumor cells, and pres-
ence of infl ammatory cells and fat necrosis (8).
Cryoablation is not recommended for in situ 
carcinoma or for lobular invasive carcinoma due 
to diffi  cult ultrasound assessment of local extent 
of the disease.
Today, the method can be routinely used to 
remove fi broadenomas, with excellent cosmetic 
results, minimal complications (10) and high level 
of patient satisfaction. After the procedure a breast 
MRI should be performed to identify potential re-
sidual disease. The presence of so called cryohalo 
indicates successful cryoablation and negative edg-
es (11). The latest cryoablation clinical study con-
ducted on 15 women with tumors 4 – 12 mm in 
diameter has shown the accuracy of MRI in detec-
tion of a solitary case of a 3 mm residual disease, 
which is considered caused by the suboptimal 
probe position during the procedure (1).
The effi  cacy of cryoablation, pre-intervention 
and post-intervention MRI is currently being re-
searched in the multi-center clinical trial Z1072 (12).
Animal models have shown antitumor im-
munity after thermoablation techniques. It is as-
sumed that the tumor-specifi c immune response 
caused by antigens from the damaged cells may 
contribute to control of thedistantmetastases (13). 
In some cases, complete tumor regression was ob-
served (14). Unlike high temperature based abla-
tion methods, cryoablation does not cause coagu-
latory necrosis, thus allowing massive antigen 
presentation in the presence of proinfl ammatory 
cytokines. Increased lymphocyte toxicity and acti-
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vation of NK cells was demonstrated in animal 
models, the activity of which is reduced in con-
ventional surgical procedures. The eff ect of cryo-
ablation stimulated anti-tumor immune response 
on recurrence and metastasis is also being exam-
ined in the clinical trial Z1072.
RADIOFREQUENCY ABLATION
In radiofrequency ablation (RFA), a metal 
electrode is inserted into the breast, which is con-
nected to a radiofrequency generator of 200 W and 
400 – 800 kHz (15-20). The electrode induces a cur-
rent which heats the surrounding tissue due to ion 
agitation (21). With heating the conductivity of the 
tissue reduces, which limits the ablation range. A 
grounding pad is placed on the skin to direct the 
current from the tissue which is further away from 
the electrode. Active cooling helps in achieving 
larger ablation zones. The placing of electrode can 
be guided by ultrasound or MRI. Nowadays, MRI 
compatible electrodes are available. Using mod-
ern, multi-shaft electrodes allows for ablation of 
greater tissue volume (3 – 6 cm) in the duration of 
10 – 15 minutes. However, due to changes in tis-
sue conductivity during heating, the ablation zone 
can be inhomogeneous and if there is no image 
control during the procedure the results of the 
procedure may be unpredictable. 
Initial feasibility studies have shown 76 – 
100 % effi  ciency of RFA in complete tumor abla-
tion (22). Due to diffi  culties in inserting multi-
shaft electrodes into solid and fi brous tissue, the 
need to use more single-shaft electrodes with the 
aim to encompass larger tissue volumes is being 
considered. However, this increases the cost and 
duration of the procedure. As with other heat 
based ablation techniques, the pain of the proce-
dure represents a problem.
MICROWAVE ABLATION
M icrowave ablation is based on electromag-
netic heating of water-rich tissue by using waves 
with the frequency from 900MHz to 2450MHz.
Two methods, which have shown diff erent results, 
are being tested. In focused microwave therapy the 
probe is placed in the center of the tumor, usually 
with ultrasound control. Patients are in a prone 
position with compressed breast, and the process 
lasts for about 60 minutes. The probe focuses mi-
crowaves and monitors the fi eld amplitude dur-
ing the procedure. A temperature probe is also 
placed in the tumor, and a cooling system is used 
to protect the skin. This method provides hetero-
geneous tumor necrosis, and complete ablation 
was achieved only in 0 – 8 % of the cases (22,23). A 
recent clinical trial demonstrated the effi  cacy of 
this method in reduction positive surgical mar-
gins and a signifi cant tumor reduction in combi-
nation with neoadjuvantchemotherapy (24). Com-
plications include severe pain and skin burns as 
well as discomfort during prolonged prone posi-
tion.
Percutaneous microwave coagulation showed 
a 90 % success rate in ablation of tumors smaller 
than 3 centimeters (25). This method is done by 
2450MHz frequency waves with a needle antenna 
in the center of the tumor. Incomplete ablations 
were explained by inadequate needle positioning 
and inaccurate pre-intervention assessment of tu-
mor extent. The procedure si performed under ul-
trasound control, and the tumor becomes echo-
genic and disappears in under 10 minutes. Down-
sides of this method are the need for general 
anesthesia and reported complications such as skin 
burns and damage to the large pectoral muscle.
FOCUSED ULTRASOUND SUR GERY
Ultrasonic energy can be used for ablation by 
using interstitial applicators or extracorporeal 
conductions into the body (21, 26-29). Extracorpo-
real ablation techniques are most often described 
using names such as Focused Ultrasound Surgery 
(FUS) and High Intensity Focused Ultrasound 
(HIFU). These systems use air-based conductors 
which are acoustically connected to the patient. 
Power of 100 W with a frequency of 1 -2 MHz is 
used for energy transfer to the target in the breast. 
In current systems there is spatial restriction of en-
ergy transfer, which is why multiple applications 
are necessary for ablation of larger tumors. Sys-
tems which would enable faster ablation of larger 
tumors are currently being researched. Diagnostic 
imaging methods are used in planning and target-
ing of tumors, and ultrasound and magnetic reso-
nance imaging are currently being tested.
Although ultrasound has the advantage of 
simplicity, speed and low cost, MRI is bett er at 
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showing soft tissue contrast and has the option to 
visualize and quantify focal warming.
The patient lies on her stomach and is acous-
tically connected to the system (30). Cooling sys-
tems are used to protect the skin. The patients are 
usually continuously intravenously sedated. MRI 
T1-W images with contrast are used for visualiza-
tion and procedure planning. Due to possible 
damage to the skin and pectoral muscle, careful 
selection of suitably located tumors is necessary. 
MRI thermal imaging (MRTI) is used to visualize 
heating of the lesions during procedure (31). Low 
energy pulses can periodically be used to localize 
the ray. The ablation procedure is performed us-
ing high energy pulses for 10 – 30 seconds for ab-
lation of volume units 1 -5 mm in diameter and 0.5 
– 3 cm in length. The ray is moved mechanically 
and electronically to achieve conformal delivery 
of multiple sonicationsto the targeted tissue. The 
temperature of targeted tissue is increased to 50 – 
90oC, with very sharp transition between treated 
and untreated tissue. Multiple sonications and 
necessary pauses between sonications result in a 
45-120 minutes procedure for tumors up to 2 cm in 
diameter.
For now, there are very few studies which 
evaluate the use of FUS in breast tumors. The fi rst 
feasibility studies show diff erent rates of complete 
ablation (24% - 100%) (32). In addition to patient 
selection, the use of this method is limited by the 
duration and pain of the procedure. Direct injec-
tion of anesthetic into the targeted area is contro-
versial because the ultrasound ray may aff ect the 
injected substance, as well as cause signifi cant 
harm to the skin at the injection point.
LASER ABLATION
Laser ablation is performed by delivering high 
energy light (800 – 1065nm) into the tissue using 
an applicator (33-35). The light absorbs in the tis-
sue around the laser , which leads to intense heat-
ing of the tissue around the applicator (21). Cool-
ing the laser catheter prevents tissue carboniza-
tion in contact with the catheter, which allows for 
use of higher power lasers for ablation of larger 
tumors. Class IV lasers are used for ablation, 
which requires adequate education, equipment 
and offi  cial registration of the user.
Ultrasound or MRI guidance can be used for 
navigation. Since there are no metal components, 
morphological and functional MRI imaging can 
be used without major artifacts. As in focused ul-
trasound ablation, MRTI can be used for localiza-
tion and monitoring the laser treatment. The size 
and strength of ablation depends on the wave 
length, power, applicator cooling and local perfu-
sion. Due to these factors, ablation can last from 90 
seconds to several minutes, and the lesion size can 
also vary from 1.5 to several centimeters. The abla-
tion zone is ellipsoidal, located centrally around 
the applicator.
The initial feasibility studies show 13 – 91% 
laser effi  ciency in complete tumor ablation (32). 
The ablation width is slightly less on average than 
those of RFA and microwave ablation, which is 
why more applications are necessary for larger 
ablations, which extends the duration of the pro-
cedure and increases costs. As with RFA, micro-
wave ablation and FUS, pain caused by the proce-
dure is a problem. 
CONCLUSION
Most clinical trials on breast cancer ablation 
were conducted on cryoablation procedures and 
RFA in second phase studies. The results show 
that the eff ectiveness of complete ablation for RFA 
is 76% - 100%, for cryoablation 36% - 93%, and for 
ultrasound ablation 20% - 100%. RFA requires lo-
cal analgesia, sedation or even general anesthesia, 
while thermal-based methods show signifi cant in-
cidence of burns, pain and patient discomfort. The 
advantages of cryoablation are simplicity, low 
equipment cost, high level of patient comfort, sa-
fety in ambulatory conditions, as well as the grow-
ing number of clinical trials. Great hopes are 
placed in the potential eff ect of ablation tech-
niques, especially cryoablation in increasing tu-
mor-specifi c immunity which could contribute to 
control of distant metastases.
In conclusion, the development of new meth-
ods for local breast cancer treatment should be en-
couraged and accepted, but with a high dose of 
criticality with the aim of providing the best pos-
sible patient care. Before introducing new meth-
ods to standard clinical application, it is necessary 
to prospectivelyevaluate the short- and long-term 
complications, such as burns, chest wall injuries, 
seroma, hematoma, cosmetic defects and, most 
importantly, incidence of local recurrence of the 
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disease.It is important to keep in mind that for ev-
ery four local recurrences avoided at fi ve years, 
one death from breast cancer is prevented at 15 
years (36). 
Also, it is important to assess patient satisfac-
tion, especially when compared to oncoplastic 
surgical procedures which show satisfactory cos-
metic results and represent the standard in today’s 
surgical treatment of breast cancer.
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